| 李 洁,霍晓颖,陈葆青,李 莉,王 婷.丹参注射液联合莫西沙星治疗老年慢阻肺急性发作患者的疗效分析[J].现代生物医学进展英文版,2019,19(13):2502-2505. |
| 丹参注射液联合莫西沙星治疗老年慢阻肺急性发作患者的疗效分析 |
| Curative Efficacy of Danshen Injection Combined with Moxifloxacin in the Treatment of Elderly Patients with AECOPD and Its Effects on the Strem-1, IL-6, CD64, and Inflammatory Factors |
| Received:January 23, 2019 Revised:February 18, 2019 |
| DOI：10.13241/j.cnki.pmb.2019.13.023 |
| 中文关键词: 丹参注射液 莫西沙星 慢性阻塞性肺疾病 可溶性髓样细胞触发受体-1 白细胞介素-6 中性粒细胞CD64 炎症因子 |
| 英文关键词: Danshen injection Moxifloxacin Chronic obstructive pulmonary disease Soluble myeloid cells trigger receptor-1 Interleukin-6 Neutrophil CD64 Inflammatory cytokines |
| 基金项目:陕西省自然科学基础研究计划项目(2014JM3586) |
| Author Name | Affiliation | E-mail | | LI Jie | Xi'an fourth Hospital Department of Respiratory Medicine, Xi'an, Shaanxi, 710000, China | zhejiangliuqian@163.com | | HUO Xiao-ying | Xi'an fourth Hospital Department of Respiratory Medicine, Xi'an, Shaanxi, 710000, China | | | CHEN Bao-qing | Xi'an fourth Hospital Department of Respiratory Medicine, Xi'an, Shaanxi, 710000, China | | | LI Li | Department of Respiratory Medicine, second affiliated Hospital of Yan'an University, Yulin, Shaanxi, 719000, China | | | WANG Ting | Xi'an fourth Hospital Department of Respiratory Medicine, Xi'an, Shaanxi, 710000, China | |
|
| Hits: 1062 |
| Download times: 764 |
| 中文摘要: |
| 摘要 目的：探讨丹参注射液联合莫西沙星治疗老年慢性阻塞性肺病急性加重患者的疗效及对血清可溶性髓样细胞触发受体-1(STREM-1)、白细胞介素-6(IL-6)、中性粒细胞CD64(CD64)及炎症因子水平的影响。方法：选择2015年5月到2017年5月我院接诊的老年慢性阻塞性肺病急性加重患者95例作为研究对象，根据随机数表法分为观察组(n=49)和对照组(n=46)。对照组使用莫西沙星治疗，观察组采用丹参注射液联合莫西沙星治疗。比较两组治疗后的疗效、治疗前后血清STREM-1、IL-6、CD64、炎症因子[肿瘤坏死因子α(TNF-α)、C反应蛋白(CRP)、降钙素原(PCT)]水平、肺功能的变化及不良反应的发生情况。结果：治疗后，观察组临床疗效总有效率为95.92%，显著高于对照组(76.09%，P＜0.05)；观察组患者血清STREM-1、IL-6、CD64、TNF-α、CRP及PCT水平均明显低于对照组(P＜0.05)；观察组FEV1、FVC、FEV1 %预测值均明显高于对照组(P＜0.05)；两组患者不良反应总发生率分别6.12%、13.04%，组间比较差异无统计学意义(P>0.05)。结论：丹参注射液联合莫西沙星治疗老年慢性阻塞性肺病患者的临床效果显著优于单用莫西沙星治疗，可能与其有效改善患者血清STREM-1、IL-6、CD64水平及炎症因子水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the curative efficacy of Danshen injection combined with moxifloxacin in the treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease and its effects on the soluble myeloid cells trigger receptor-1 (strem-1), interleukin-6 (il-6), neutrophil CD64 (CD64), and inflammatory factors. Methods: 95 elderly patients with chronic obstructive pulmonary disease treated in our hospital from May 2015 to May 2017 were selected and divided into the observation group (n=49) and the control group (n=46) according to the randomized table. The control group was treated with moxifloxacin, and the observation group was treated with moxifloxacin combined with moxifloxacin. After treatment, the clinical effects, changes of serum sTREM-1, IL-6, CD64, TNF-α, c-reactive protein (CRP), calcitonin (PCT), lung function and incidence of adverse reactions were compared between two groups. Results: After treatment, the total effective rate of observation group was 95.92%, which was significantly higher than that of the control group (76.09%, P<0.05). The serum sTREM-1, IL-6, CD64, TNF-α, CRP and PCT levels in the observation group were significantly lower than those in the control group (P<0.05). The predictive values of FEV1, FVC and FEV1 % in the observation group were significantly higher than those in the control group (P<0.05). The total incidence of adverse reactions in the two groups was 6.12% and 13.04%, respectively, and no statistically significant difference was found between the two groups(P>0.05). Conclusion: The clinical effect of salvia miltiorrhiza injection combined with moxifloxacin is significantly better than that of moxifloxacin alone in the treatment of elderly patients with chronic obstructive pulmonary disease, which may be related to its effective improvement of serum sTREM-1, IL-6, CD64 and inflammatory factor levels. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
